Environmental Mutagenesis & Genomics Society

50th Annual Meeting, Washington DC

September 19-23, 2019 - Capital Hilton Washington DC

Environmental Mutagenesis and Genomics: The Next Fifty Years

 Important Dates

Registration

3/4/19-Registration is now Open
7/27/19-Early Bird Registration Ends
8/19/19-Advanced Registration Ends

Abstracts

2/22/19-Abstract Submission is now Open
5/1/19-Abstract Submission Deadline
8/29/19-Late Abstracts Deadline

Travel Awards

Travel Award Form Available
5/1/19-Travel Award Deadline

Hotel Information

2/27/19-Reservations Open
8/21/19-Reservation Deadline


EMGS Welcomes You

The EMGS welcomes members and attendees from across the US and around the world. Our diversity is essential to our success, and as your national professional society, we are committed to providing a safe and supportive forum for the communication of world-class science. The EMGS Diversity and Inclusion committee sends a special welcome to members of the LGBT community.  Please reach out to any member of the EMGS Diversity and Inclusion Committee with your comments.

EMGS Workshops

September 19th, 2019

8:00 AM - 12:00 PM

Scientific and Regulatory Updates on Non-Mutagenic and Mutagenic Impurities in Pharmaceuticals

Chair: Patricia Escobar, Merck Inc.


Update of IQ consortium – Non mutagenic impurities (NMI)

Joel Bercu, Gilead USA

Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.

TBD

Considerations for Deriving NMI Exposure Limits

Mark Powley, Merck Research Laboratories USA

Update on the regulatory status on NDMA & NDEA in Valsartan products

Brinda Mahadevan, Abbott Laboratories

ICH M7 and Biotherapeutics: Out of Scope but Relevant

Zhanna Sobol, Pfizer USA

Update on the DrugSafe IQ consortium on mutagenic Impurities (QSAR review of impurities)

John Nicolette, AbbVie USA

Regulatory perspective

TBD

Q&A followed by a panel discussion

9:00 AM - 3:30 PM

Heritable Hazards of Smoking: Applying the “Clean Sheet” Framework to Further Science and Policy

Co-chairs: David M. DeMarini, US EPA, Carole L. Yauk, Health Canada, Francesco Marchetti, Health Canada, Jill Escher, Escher Fund for Autism

8:45-9:00 AM
Welcome, Opening Remarks, and Introductions,
Jill Escher, Escher Fund for Autism

9:00-9:20 AM
The Clean Sheet Initiative and Its Potential to Identify the Risks of Heritable Consequences of Tobacco Smoke Exposures
Kerry L. Dearfield, USDA

9:20-9:45 AM
Rationale for This Workshop: Growing Concern Regarding Heritable and Intergenerational Effects from Environmental Exposures 
Carole L. Yauk, Health Canada

9:45-10:00 AM
The Heritable Consequences of Tobacco Smoke Exposure 
David M. DeMarini, US EPA, RTP, NC

10:00-10:15 AM
The Potentially Vulnerable Periods of Exposure to the Male and Female Germline 
Jacquetta Trasler, McGill University, Montreal, ON, Canada

10:15-10:30 AM
Coffee Break

10:30-10:50 AM
Tobacco-Induced Male Germ-Cell and Heritable Effects 
Francesco Marchetti, Health Canada

10:50-11:10 AM
Male-Mediated Heritable Epigenetic Effects 
Jacquetta Trasler, McGill University, Montreal, ON, Canada

11:10-11:30 AM
Overview of Asthma and Allergy Epidemiology: Epigenetic Studies of Transgenerational Effects of Smoking
John Holloway, University of Southhampton, UK

11:30-11:50 AM
Multigenerational Transmission of Hyperactivity/ADHD
Pradeep Bhide, Florida State University, Tallahassee, FL, USA

11:50-12:10 PM
The RHINESSA Cohort, a Three-Generation Study on the Association of Tobacco Smoking with Asthma 
Cecillie Svanes,

12:10-12:30 PM
Discussion of the Evidence

12:30-1:30 PM
Lunch (provided)

1:30-2:30 PM
Regulatory Perspectives

2:30-3:25 PM
Summary of Methods and Data Sets Useful for Studying Intergenerational Effects of These Products and How to Apply the Clean Sheet Initiative

Structured open discussion consisting of questions and consensus statements

What are the gaps and what research is needed?

The regulatory paradigm and policy: what it is currently and how it could be changed?

3:25-3:30 PM
Closing Remarks
Jill Escher, Escher Fund for Autism

12:00 - 4:30 PM

OECD Assessment of Miniaturized Ames Assays: Results and Recommendations

Co-chairs: Birgit Mertens, Sciensano, Brussels, Belgium, Leon F. Stankowski, Jr. Charles River Laboratories, Skokie, IL, USA

12:00-12:15 PM
Pick up Box Lunch (provided)

12:15-12:30 PM
Overview of OECD Process to Evaluate Miniaturized Ames Assays 
Birgit Mertens, Sciensano, Brussels, Belgium

12:30-1:00 PM
The 6-Well Ames Assay
John Nicolette, AbbVie, North Chicago, IL, USA

1:00-1:30 PM
The 24-Well Ames Assay
Leon F. Stankowski, Jr., Charles River Laboratories, Skokie, IL, USA

1:30-2:00 PM
The Ames II/MPF Assay
Kamala Pant, BioReliance, Rockville, MD, USA

2:00-2:30 PM
Technical Comparisons Among Assays
Birgit Mertens, Sciensano, Brussels, Belgium

2:30-3:00 PM
Coffee Break

3:00-3:45 PM
Qualitative and Quantitative Comparisons of Assays
Paul White, Health Canada

3:45-4:30 PM
Discussion and Closing Summary
Birgit Mertens, Sciensano, Brussels, Belgium